The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Development of Pharmaceutical Nanomedicines: From the Bench to the Market
Open accessAbstract
Nanotechnology plays a significant role in the field of medicine and in drug delivery, mainly due to the major limitations affecting the conventional pharmaceutical agents, and older formulations and delivery systems. The effect of nanotechnology on healthcare is already being felt, as various nanotechnology applications have been developed, and several nanotechnology-based medicines are now on the market. Across many parts of the world, nanotechnology draws increasing investment from public authorities and the private sector. Most conventional drug-delivery systems (CDDSs) have an immediate, high drug release after administration, leading to increased administration frequency. Thus, many studies have been carried out worldwide focusing on the development of pharmaceutical nanomedicines for translation into products manufactured by local pharmaceutical companies. Pharmaceutical nanomedicine products are projected to play a major role in the global pharmaceutical market and healthcare system. Our objectives were to examine the nanomedicines approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the global market, to briefly cover the challenges faced during their development, and to look at future perspectives. Additionally, the importance of nanotechnology in developing pharmaceutical products, the ideal properties of nanocarriers, the reasons behind the failure of some nanomedicines, and the important considerations in the development of nanomedicines will be discussed in brief.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxic potential of materials at the nanolevel
Nel, A., Xia, T., Mädler, L., & Li, N. (2006) · Science · doi:10.1126/science.1114397 · Cited by 9,324
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers
Ensign, L. M., Cone, R., & Hanes, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.009 · Cited by 1,623
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Cone, R. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.008 · Cited by 1,459
Wang, Y.-X. J., Hussain, S. M., & Krestin, G. P. (2001) · European Radiology · doi:10.1007/s003300100908 · Cited by 1,381
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
Blood-brain barrier tight junction permeability and ischemic stroke
Sandoval, K. E., & Witt, K. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.005 · Cited by 964
Nanocrystal technology, drug delivery and clinical applications
Müller, R., & Junghanns (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s595 · Cited by 953
Sheridan, W. P., Fox, R. M., Begley, C. G., Maher, D., McGrath, K. M., Begley, C. G., Juttner, C. A., To, L. B., Szer, J., & Mostyn, G. (1992) · The Lancet · doi:10.1016/0140-6736(92)90795-5 · Cited by 857
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 835
Delivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798
Nanomedicine: Principles, Properties, and Regulatory Issues
Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00360 · Cited by 790
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 1×
“FDA (2005, 2012, 2013), EMA (2008) paclitaxel approved by the FDA for treatment of metastatic breast cancer [127] (2005), lung cancer [128] (2012), and metastatic pancreatic adenocarcinoma [129] (2013)”
BackgroundBatist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Zhang, X., Lin, Y., & Gillies, R. J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.068981 · Cited by 659
Van den Eynde, B. J., & van der Bruggen, P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80050-7 · Cited by 623
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Nanoparticles and nanofibers for topical drug delivery
Goyal, R., Macri, L. K., Kaplan, H. M., & Kohn, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.049 · Cited by 590
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 588
Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021) · PubMed · doi:10.26355/eurrev_202102_24877 · Cited by 564
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 546
Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M., Curran, K. G., Chamberland, M., McClung, N., Campos-Outcalt, D., Morgan, R. L., Mbaeyi, S., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950e2 · Cited by 536
Glantz, M., Jaeckle, K. A., Chamberlain, M. C., Phuphanich, S., Recht, L. D., Swinnen, L. J., Maria, B., LaFollette, S., Schumann, G. B., Cole, B. F., et al. (1999) · PubMed · Cited by 529
A Review of Clinical Translation of Inorganic Nanoparticles
Anselmo, A. C., & Mitragotri, S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9780-2 · Cited by 509
Brain barrier systems: a new frontier in metal neurotoxicological research
Zheng, W., Aschner, M., & Ghersi-Egea, J.-F. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(03)00251-5 · Cited by 507
Drug Delivery and Transport to Solid Tumors
Jang, S. H., Wientjes, M. G., Lu, D., & Au, J. L.-S. (2003) · Pharmaceutical Research · doi:10.1023/a:1025785505977 · Cited by 483
Landewé, R., Braun, J., Deodhar, A. A., Dougados, M., Maksymowych, W. P., Mease, P. J., Reveille, J. D., Rudwaleit, M., van der Heijde, D. M. F. M., Stach, C. M., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204231 · Cited by 470
Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma
Song, Y., Li, X., & Du, X. (2009) · European Respiratory Journal · doi:10.1183/09031936.00178308 · Cited by 448
Choi, Y. H., & Han, H.-K. (2018) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0370-4 · Cited by 406
Delivering the power of nanomedicine to patients today
Germain, M., Caputo, F., Metcalfe, S., Tosi, G., Spring, K., Åslund, A. K. O., Pottier, A., Schiffelers, R., Ceccaldi, A., & Schmid, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.007 · Cited by 405
Gene therapy progress and prospects: non-viral gene therapy by systemic delivery
Li, S.-D., & Huang, L. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302838 · Cited by 391
Drummond, D. C., Noble, C. O., Guo, Z., Hong, K., Park, J. W., & Kirpotin, D. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4007 · Cited by 380
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
Trickler, W. J., Lantz, S. M., Murdock, R. C., Schrand, A. M., Robinson, B. L., Newport, G. D., Schlager, J. J., Oldenburg, S. J., Paule, M. G., Slikker, W., et al. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq244 · Cited by 346
Stephan, J. L., Vlekova, V., Deist, F. L., Blanche, S., Donadieu, J., Saint-Basile, G. D., Durandy, A., Griscelli, C., & Fischer, A. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80951-5 · Cited by 344
Barriers to drug delivery in solid tumors
Sriraman, S. K., Aryasomayajula, B., & Torchilin, V. P. (2014) · Tissue Barriers · doi:10.4161/tisb.29528 · Cited by 338
Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., & Sharpington, T. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3093 · Cited by 336
Krauss, A. C., Gao, X., Li, L., Manning, M. L., Patel, P., Fu, W., Janoria, K. G., Gieser, G., Bateman, D. A., Przepiorka, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2990 · Cited by 332
Prasad, M., Lambe, U. P., Brar, B., Shah, I., J, M., Ranjan, K., Rao, R., Kumar, S., Mahant, S., Khurana, S. K., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.026 · Cited by 327
Jacobson, I. M., Brown, R. S., Freilich, B., Afdhal, N., Kwo, P. Y., Santoro, J., Becker, S., Wakil, A. E., Pound, D., Godofsky, E., et al. (2007) · Hepatology · doi:10.1002/hep.21932 · Cited by 304
Slatopolsky, E. A., Burke, S. K., & Dillon, M. A. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00240.x · Cited by 302
RNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 286
Expression of MAGE genes in primary and metastatic cutaneous melanoma
Brasseur, F., Rimoldi, D., Liénard, D., Lethé, B., Carrel, S., Arienti, F., Suter, L., Vanwijck, R., Bourlond, A., Humblet, Y., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630313 · Cited by 285
Cheng, Y., Dai, Q., Morshed, R. A., Fan, X., Wegscheid, M. L., Wainwright, D. A., Han, Y., Zhang, L., Auffinger, B., Tobias, A. L., et al. (2014) · Small · doi:10.1002/smll.201400654 · Cited by 271
Koffie, R. M., Farrar, C. T., Saidi, L.-J., William, C. M., Hyman, B. T., & Spires-Jones, T. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111405108 · Cited by 260
Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment.
Wong, C. Y., Al-Salami, H., & Dass, C. R. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.003 · Cited by 257
Nanomedicine: Application of Nanobiotechnology in Medical Practice
Jain, K. K. (2008) · Medical Principles and Practice · doi:10.1159/000112961 · Cited by 247
Kruit, W. H. J., Suciu, S., Dreno, B., Mortier, L., Robert, C., Chiarion-Sileni, V., Maio, M., Testori, A., Dorval, T., Grob, J.-J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7111 · Cited by 227
Caldwell, J. R., Rapoport, R. J., Davis, J. C., Offenberg, H. L., Marker, H. W., Roth, S. H., Yuan, W., Eliot, L., Babul, N., & Lynch, P. M. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00383-4 · Cited by 219
Expression of MAGE-antigens in normal tissues and cancer
Jungbluth, A. A., Busam, K. J., Kolb, D., Iversen, K., Coplan, K., Chen, Y.-T., Spagnoli, G. C., & Old, L. J. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000215)85:4<460::aid-ijc3>3.0.co;2-n · Cited by 217
To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes
Dou, Y., Hynynen, K., & Allen, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.025 · Cited by 210
Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?
Mühlebach, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.024 · Cited by 203
Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds
Rivera Gil, P., Hühn, D., del Mercato, L. L., Sasse, D., & Parak, W. J. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.009 · Cited by 202
Ragelle, H., Riva, R., Vandermeulen, G., Naeye, B., Pourcelle, V., Le Duff, C. S., D'Haese, C., Nysten, B., Braeckmans, K., De Smedt, S. C., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.12.026 · Cited by 200
Immunogenicity of new virosome influenza vaccine in elderly people
Glück, R., Mischler, R., Finkel, B., Que, J. U., Cryz, S. J., & Scarpa, B. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92758-8 · Cited by 199
Suk, J. S., Lai, S. K., Boylan, N. J., Dawson, M. R., Boyle, M. P., & Hanes, J. (2011) · Nanomedicine · doi:10.2217/nnm.10.123 · Cited by 185
Spuch, C., & Navarro, C. (2011) · Journal of Drug Delivery · doi:10.1155/2011/469679 · Cited by 177
Emerging trends of nanomedicine – an overview
Sandhiya, S., Dkhar, S. A., & Surendiran, A. (2009) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00692.x · Cited by 174
The Run on Ritalin: Attention Deficit Disorder and Stimulant Treatment in the 1990s
Diller, L. H. (1996) · The Hastings Center Report · doi:10.2307/3528571 · Cited by 172
Johnston, M., Semple, S. C., Klimuk, S. K., Edwards, K., Eisenhardt, M. L., Leng, E. C., Karlsson, G., Yanko, D., & Cullis, P. R. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.01.009 · Cited by 172
Li, L., Wartchow, C. A., Danthi, S. N., Shen, Z., Dechene, N., Pease, J., Choi, H. S., Doede, T., Chu, P., Ning, S., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.10.057 · Cited by 161
Kruit, W. H. J., van Ojik, H. H., Brichard, V. G., Escudier, B. J., Dorval, T., Dréno, B., Patel, P. M., van Baren, N., Avril, M., Piperno‐Neumann, S., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21264 · Cited by 160
Atanackovic, D., Altorki, N. K., Cao, Y., Ritter, E., Ferrara, C. A., Ritter, G., Hoffman, E. W., Bokemeyer, C., Old, L. J., & Gnjatic, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707140104 · Cited by 158
Regulating Nanomedicine at the Food and Drug Administration
Paradise, J. K. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.347 · Cited by 152
Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution
Vergoni, A. V., Tosi, G., Tacchi, R., Vandelli, M. A., Bertolini, A., & Costantino, L. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.02.005 · Cited by 150
Nanomedicines: from bench to bedside and beyond.
Havel, H., Finch, G., Strode, P., Wolfgang, M., Zale, S., Bobe, I., Youssoufian, H., Peterson, M., & Liu, M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9961-7 · Cited by 149
Sevelamer Crystals in the Gastrointestinal Tract (GIT)
Swanson, B. J., Limketkai, B. N., Liu, T., et al. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182999d8d · Cited by 148
Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
Franco, Y. L., Vaidya, T. R., & Ait‐Oudhia, S. (2018) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s170239 · Cited by 137
Schwenk, M. H. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.1.70 · Cited by 136
Pillai, G. (2014) · SOJ Pharmacy & Pharmaceutical Sciences · doi:10.15226/2374-6866/1/1/00109 · Cited by 135
Intra-articular drug delivery systems for joint diseases
Rai, M. F., & Pham, C. T. N. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.013 · Cited by 132
Liposomal daunorubicin as treatment for Kaposi’s sarcoma
Dittmer, D. P., & Petre, C. E. (2007) · PubMed Central · doi:10.17615/wyf0-9n94 · Cited by 130
Krishna, R., Webb, M. S., St.-Onge, G., & Mayer, L. D. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29494-5 · Cited by 129
Mifamurtide: A Review of its Use in the Treatment of Osteosarcoma
Frampton, J. E. (2010) · Pediatric Drugs · doi:10.2165/11204910-000000000-00000 · Cited by 128
Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer
Tejada‐Berges, T., Granai, C. O., Gordinier, M. E., & Gajewski, W. H. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.2.143 · Cited by 125
How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
Schellekens, H., Stegemann, S., Weinstein, V., de Vlieger, J. S. B., Flühmann, B., Mühlebach, S., Gaspar, R. S., Shah, V. P., & Crommelin, D. J. A. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9533-z · Cited by 122
Nanoparticulate Drug-Delivery Systems: An Overview
Thassu, D., Pathak, Y. V., & Deleers, M. (2007) · CRC Press eBooks · doi:10.1201/9781420008449-1 · Cited by 114
Auerbach, M., Pappadakis, J. A., Bahrain, H., Auerbach, S. A., Ballard, H. S., & Dahl, N. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.22153 · Cited by 113
Effects of High‐Energy Electrons and Gamma Rays Directly on Protein Molecules
Kempner, E. S. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1114 · Cited by 112
Bozdag, S., Dillen, K., Vandervoort, J., & Ludwig, A. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357056145 · Cited by 107
Conne, P., Gauthey, L., Vernet, P., Althaus, B., Que, J. U., Finkel, B., Glück, R., & Cryz, S. J. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00087-x · Cited by 106
Rizzieri, D. A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.07.008 · Cited by 100
Bernocchi, B., Carpentier, R., & Betbeder, D. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.012 · Cited by 99
Nanoparticle-Based Drugs and Formulations: Current Status and Emerging Applications
Kumar, R., Dalvi, S. V., & Siril, P. F. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c00606 · Cited by 96
Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease
Coyne, D. W. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903224998 · Cited by 95
Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review
Grabrucker, A. M., Rowan, M., & Garner, C. C. (2011) · Drug Delivery Letters · doi:10.2174/2210303111101010013 · Cited by 95
Fütterer, S., Andrusenko, I., Kolb, U., Hofmeister, W., & Langguth, P. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.08.005 · Cited by 93
Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma
Sharma, P., Shen, Y., Wen, S., Bajorin, D. F., Reuter, V. E., Old, L. J., & Jungbluth, A. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0527 · Cited by 92
Equivalence of complex drug products: advances in and challenges for current regulatory frameworks
Hussaarts, L., Mühlebach, S., Shah, V. P., McNeil, S. E., Borchard, G., Flühmann, B., Weinstein, V., Neervannan, S., Griffiths, E., Jiang, W., et al. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13347 · Cited by 90
LISTER, J. W. (1996) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1996.tb01348.x · Cited by 81
Expression of cancer-testis genes in human hepatocellular carcinomas.
Luo, G., Huang, S., Xie, X., Stockert, E., Chen, Y., Kubuschok, B., & Pfreundschuh, M. G. (2002) · PubMed · Cited by 78
Klein, K., Stolk, P., Bruin, M. L. D., Leufkens, H. G. M., Crommelin, D. J. A., & de Vlieger, J. S. B. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.03.029 · Cited by 76
Certolizumab pegol for the treatment of Crohn’s disease
Schreiber, S. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11413315 · Cited by 74
Pillai, G., & Ceballos-Coronel, M. L. (2013) · SAGE Open Medicine · doi:10.1177/2050312113513759 · Cited by 71
(2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2017.26590.6513 · Cited by 69
Chavez, B., Sopko, M. A., Ehret, M. J., Paulino, R. E., Goldberg, K. R., Angstadt, K., & Bogart, G. T. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l523 · Cited by 68
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties
Nyborg, A. C., Ward, C., Zacco, A., Chacko, B. M., Grinberg, L., Geoghegan, J. C., Bean, R., Wendeler, M., Bartnik, F., O’Connor, E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167935 · Cited by 63
Borgå, O., Lilienberg, E., Bjermo, H., Hansson, F., Heldring, N., & Dediu, R. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01058-6 · Cited by 57
Astier, A., Pai, A. B., Bissig, M., Crommelin, D. J. A., Flühmann, B., Hecq, J., Knoeff, J., Lipp, H., Baladrón, A. M., & Mühlebach, S. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13382 · Cited by 51
Narayan, R., Pednekar, A., Bhuyan, D., Gowda, C., Koteshwara, K. B., & Nayak, U. Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s141504 · Cited by 49
The Ethical Dimensions of Nanomedicine
Bawa, R., & Johnson, S. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.05.007 · Cited by 48
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
Choi, M., Al‐Hajeili, M., & Azmi, A. S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s40705 · Cited by 46
Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension
Musaji, N. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s6308 · Cited by 44
Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency
Macdougall, I. C., Colet, J. C., Breymann, C., Spahn, D. R., & Κoutroubakis, I. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01323-z · Cited by 44
Clarke, P. D., Adams, P., Ibáñez, R., & Herzog, C. (2006) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2006.01.001 · Cited by 43
Alagona, P. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6714 · Cited by 42
Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability
Berges, R. R. (2005) · European Urology Supplements · doi:10.1016/j.eursup.2005.04.001 · Cited by 38
Cyclosporine A micellar delivery system for dry eyes
Hwang, S., Kang, H. S., Cha, K.-H., Cho, W., Park, J. S., Park, H. J., Sun, B. K., & Hyun, S.-M. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s107569 · Cited by 35
Andrews, P. L. R., Kovacs, M., & Watson, J. W. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02269-8 · Cited by 34
Nanotechnology in Drug Development and Life Cycle Management
Majuru, S., & Oyewumi, M. O. (2008) · Springer eBooks · doi:10.1007/978-0-387-77668-2_20 · Cited by 33
Tizanidine (Zanaflex): A Muscle Relaxant That May Prolong the QT Interval by Blocking I Kr
Kaddar, N., Vigneault, P., Pilote, S., Patoine, D., Simard, C., & Drolet, B. (2011) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248410395020 · Cited by 31
Duvic, M. A. (2000) · Clinical Lymphoma · doi:10.3816/clm.2000.s.010 · Cited by 31
Transdermal menopausal hormone therapy: delivery through skin changes the rules
Buster, J. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003774098 · Cited by 31
Lim, E.-A., Sohn, H.-S., Lee, H., & Choi, S.-E. (2014) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-12-19 · Cited by 26
Zhou, H., Yan, J., Chen, W., Yang, J., Liu, M., Zhang, Y., Shen, X., Ma, Y., Hu, X., Wang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.01731 · Cited by 22
Melamed‐Gal, S., Loupe, P. S., Timan, B., et al. (2018) · eNeurologicalSci · doi:10.1016/j.ensci.2018.05.006 · Cited by 20
Cost-Effectiveness of Genexol-PM for Treating Metastatic Breast Cancer
Kim, J., & Shin, S. (2010) · Journal of Breast Cancer · doi:10.4048/jbc.2010.13.1.104 · Cited by 18
Garnock-Jones, K. P. (2016) · Drugs · doi:10.1007/s40265-016-0627-7 · Cited by 16
Gharehbaghi, M. M., & Yasrebi, S. (2014) · International Journal of Women s Health and Reproduction Sciences · doi:10.15296/ijwhr.2014.36 · Cited by 10
Pegaptanib for Neovascular Age-Related Macular Degeneration
Penman, A. D., Crowder, K. W., & Watkins, W. M. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780190050726.003.0039 · Cited by 7
Cited by
Effects of nanoparticle size, shape, and zeta potential on drug delivery
Öztürk, K., Kaplan, M., & Çalış, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124799 · Cited by 449
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
Kim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
Artificial Intelligence Advancements in Oncology: A Review of Current Trends and Future Directions
Huhulea, E. N., Huang, L., Eng, S., Sumawi, B., Huang, A., Aifuwa, E., Hirani, R., Tiwari, R. K., & Etienne, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040951 · Cited by 74
Arunachalam, K., Pandurangan, P., Shi, C., & Lagoa, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020310 · Cited by 48
Metadata
- Authors
- Halwani, A. A.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-01-03
- Volume
- 14
- Issue
- 1
- Pages
- 106
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W4205647138
- Cited by
- 324
- References
- 137
- FWCI
- 14.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.